Perceived Acquired Resistance to Omalizumab in Obese Patients With Chronic Spontaneous Urticaria
Open Access
- 8 February 2026
- journal article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (6) , 671-673
Abstract
Summary: Obese patients with chronic spontaneous urticaria often require progressively increasing omalizumab doses to maintain previous disease control. Acquired resistance to omalizumab may be explained by immunological and pharmacokinetic changes in the setting of obesity.Keywords
This publication has 8 references indexed in Scilit:
- Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational studyAllergy, 2024
- Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three‐month prospective studyClinical & Experimental Allergy, 2022
- Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) UrticariaJAMA Dermatology, 2019
- Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticariaBritish Journal of Dermatology, 2018
- The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticariaAllergy, 2018
- Leptin Enhances TH2 and ILC2 Responses in Allergic Airway DiseaseJournal of Biological Chemistry, 2016
- Structural basis of omalizumab therapy and omalizumab-mediated IgE exchangeNature Communications, 2016
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001